翰思艾泰启动港股IPO 推出靶向Tregs新一代免疫疗法

DoNews12-17

翰思艾泰于12月15日开启港交所18A章上市招股，成为2025年备受关注的新一代Biotech企业。公司核心管线聚焦调节性T细胞（Tregs）调控，布局多款创新机制药物。其在研产品HX044为全球首创CTLA-4/SIRPα融合蛋白，通过双靶向设计选择性清除肿瘤微环境（TME）中的Tregs，具备治疗PD-(L)1耐药泛实体瘤潜力。该分子采用“双弱”策略降低全身毒性，在临床前模型中显示优于伊匹木...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592912699?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-17 08:53","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2592912699","market":"hk","top_or_hot":-1,"title":"翰思艾泰启动港股IPO 推出靶向Tregs新一代免疫疗法","media":"DoNews","content":"<div>\n<p>翰思艾泰于12月15日开启港交所18A章上市招股，成为2025年备受关注的新一代Biotech企业。公司核心管线聚焦调节性T细胞（Tregs）调控，布局多款创新机制药物。其在研产品HX044为全球首创CTLA-4/SIRPα融合蛋白，通过双靶向设计选择性清除肿瘤微环境（TME）中的Tregs，具备治疗PD-(L)1耐药泛实体瘤潜力。该分子采用“双弱”策略降低全身毒性，在临床前模型中显示优于伊匹木...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰思艾泰启动港股IPO 推出靶向Tregs新一代免疫疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰思艾泰启动港股IPO 推出靶向Tregs新一代免疫疗法\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 08:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b><strong>DoNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>翰思艾泰于12月15日开启港交所18A章上市招股，成为2025年备受关注的新一代Biotech企业。公司核心管线聚焦调节性T细胞（Tregs）调控，布局多款创新机制药物。其在研产品HX044为全球首创CTLA-4/SIRPα融合蛋白，通过双靶向设计选择性清除肿瘤微环境（TME）中的Tregs，具备治疗PD-(L)1耐药泛实体瘤潜力。该分子采用“双弱”策略降低全身毒性，在临床前模型中显示优于伊匹木...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b","article_id":"2592912699","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085812a4546592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592912699","pubTimestamp":1765932783,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"翰思艾泰于12月15日开启港交所18A章上市招股，成为2025年备受关注的新一代Biotech企业。公司核心管线聚焦调节性T细胞调控，布局多款创新机制药物。HX044已获国内联用PD-1抑制剂临床批件。翰思艾泰作为少数拥有两款MCE临床阶段管线的公司之一，具备较强对外授权可能性。BioNTech、和铂医药、中生制药等企业亦在推进靶向TME中Tregs的新型CTLA-4疗法。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03378":"翰思艾泰-B","BK1173":"海港与服务","BK1535":"港口运输股"},"translate_title":"Hans Aitai launches Hong Kong IPO to launch a new generation of immunotherapy targeting Tregs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":0.9},"content_text":"翰思艾泰于12月15日开启港交所18A章上市招股，成为2025年备受关注的新一代Biotech企业。公司核心管线聚焦调节性T细胞（Tregs）调控，布局多款创新机制药物。其在研产品HX044为全球首创CTLA-4/SIRPα融合蛋白，通过双靶向设计选择性清除肿瘤微环境（TME）中的Tregs，具备治疗PD-(L)1耐药泛实体瘤潜力。该分子采用“双弱”策略降低全身毒性，在临床前模型中显示优于伊匹木单抗的抗肿瘤活性和更宽治疗窗口，并已在中澳开展I期临床试验，预计2026年上半年公布初步数据。HX044已获国内联用PD-1抑制剂临床批件。HX009是另一款PD-1/SIRPα双功能融合蛋白，属于髓系细胞衔接器（MCE）技术平台产品。该管线采取差异化临床路径，优先推进EBV阳性非霍奇金淋巴瘤及晚期黑色素瘤注册性II/III期研究。其Ib期临床观察到一例HER2低表达/超低表达三阴乳腺癌患者持续超过一年半的部分缓解（PR）。2025年2月，该药获批开展联合DS-8201治疗不可切除或转移性TNBC的II期临床。MCE平台因在冷肿瘤治疗中的潜力受到国际药企关注，诺华、辉瑞、赛诺菲等已与多家拥有同类技术的企业达成高额合作。翰思艾泰作为少数拥有两款MCE临床阶段管线的公司之一，具备较强对外授权可能性。公司另有autoRx40技术平台衍生出OX40双表位双抗HX035、OX40/自免靶点双抗HX038及OX40抗体偶联药物HX111。HX035拟用于急性移植物抗宿主病（GvHD），即将进入IND阶段；HX111已进入临床阶段，针对亚型淋巴瘤、白血病及部分实体瘤。其他早期管线包括TRBV12 ADC、NKG2A单抗、PD-(L)1/VEGF双抗以及与Traws Pharma合作开发的胶质母细胞瘤药物HX301。公司通过授权乐普生物PD-1单抗获得4.375%净销售额分成，形成稳定现金流支撑研发。BioNTech、和铂医药、中生制药等企业亦在推进靶向TME中Tregs的新型CTLA-4疗法。其中BioNTech的Gotistobart在sqNSCLC和MSS CRC中显示出显著生存获益。现有证据表明，CTLA-4抑制剂与PD-1/PD-L1抑制剂联用可增强疗效，且“O药+Y药”方案已在黑色素瘤和肝癌中获批应用。基于HER2低表达占乳腺癌总体45%-65.5%，其中三阴性乳腺癌占比不低于32%，HX009联合DS-8201有望切入年均约10亿美元、增速达12%-14%的二至三线治疗市场。参考Gotistobart早期即达成2亿美元首付的合作案例，HX044作为First-in-class候选药物具潜在海外交易价值。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592912699","isCrawlerRequest":true}